Mueller, Christoph http://orcid.org/0000-0001-9816-1686
John, Christeena
Perera, Gayan
Aarsland, Dag
Ballard, Clive
Stewart, Robert
Funding for this research was provided by:
National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London
Article History
Received: 28 January 2019
Accepted: 2 May 2020
First Online: 15 May 2020
Compliance with ethical standards
:
: RS has received research funding from Roche, Pfizer, Janssen, Lundbeck and In-Silico-Bioscience. DA has received research support and/or honoraria from Astra-Zeneca, H. Lundbeck, Novartis Pharmaceuticals and GE Health, and serves as paid consultant for H. Lundbeck and Axovant. CB has received honoraria and grant funding from Acadia pharmaceuticals, Lundbeck, Takeda and Axovant pharmaceutical companies. CB leads the Alzhiemer’s disease psychosis (ADP) investigators group. Honoraria from Lundbeck, Lilly, Otusaka and Orion pharmaceutical companies. CM, CJ and GP declare no conflict of interest.